FDA Drug recall D-0219-2019
Contrave (naltrexone HCl and bupropion HCl)
- FDA Drug
- Class III
- terminated
- Published 2018-11-14
On 2018-11-14 the FDA classified a Class III recall of Contrave (naltrexone HCl and bupropion HCl) by Orexigen Therapeutics, citing container packaging defect.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0219-2019 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2018-10-05 |
| Published | 2018-11-14 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Orexigen Therapeutics |
| Distribution | n/a |
Product
Contrave (naltrexone HCl and bupropion HCl). Extended-Release Tablets, 8mg/90 mg, 120-count bottles, Rx only, Distributed by Orexigen therapeutics, Inc., La Jolla, CA 92037, NDC 51267-890-99
Reason
Container packaging defect.
Identifiers
| ndc | 51267-890-99 |
|---|---|
| ndc | 51267-890-07 |
| code_info | Lot #: ZYCY, Exp. 04/11/2021 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0219-2019%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.